FindTrial
Sign In

2:16DU-ml

3 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

Booster vaccination against Streptococcus pneumoniae in children 12 to 18 months old.Booster vaccination against Streptococcus pneumoniae or Haemophilus influenzae in healthy infants 12 to 18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine in the primary vaccination study 10PN-PD-DIT-012 (107007).Catch-up immunization against Streptococcus pneumoniae in children older than 7 months at the time of the first vaccination and subdivided according to the age: • 7 to 11 months of age. • 12 to 23 months of age. • 24 months to 5 years of age.

Phase 3

A phase IIIb, observer-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a booster dose between 12-18 months of age in children previously vaccinated in the primary study 10PN-PD-DIT-012 (107007) with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar. - 10PN-PD-DIT-018 BST:012
EUCTR2006-005891-41-PL
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae or Haemophilus influenzae in healthy infants 12 to 18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine in the primary vaccination study 10PN-PD-DIT-012 (107007).
Target: 806Updated: 2017-10-02

Unknown Phase

A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up immunization in children older than 7 months of age or given as a 3-dose primary immunization in children before 6 months of age. - 10PN-PD-DIT-013
Active, not recruitingEUCTR2006-001482-42-FI
GlaxoSmithKline BiologicalsCatch-up immunization against Streptococcus pneumoniae in children older than 7 months at the time of the first vaccination and subdivided according to the age: • 7 to 11 months of age. • 12 to 23 months of age. • 24 months to 5 years of age.
Start: 2006-07-07Target: 600Updated: 2012-03-19
A phase IIIa single-blind, controlled multicentre study to assess the safety, reactogenicity and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar when given as a fourth dose between 12-18 months of age in children previously vaccinated in infancy in the primary study 10PN-PD-DIT-001 (105553) with either GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar. - 10PN-PD-DIT-007 BST: 001
Active, not recruitingEUCTR2006-001628-38-FI
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae in children 12 to 18 months old.
Start: 2006-07-26Target: 1200Updated: 2012-03-19